Critical Analysis: PMV Pharmaceuticals (NASDAQ:PMVP) vs. XOMA (NASDAQ:XOMAP)

PMV Pharmaceuticals (NASDAQ:PMVP) and XOMA (NASDAQ:XOMAP) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.

Profitability

This table compares PMV Pharmaceuticals and XOMA’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PMV Pharmaceuticals	N/A	-78.11%	-70.13%
XOMA	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for PMV Pharmaceuticals and XOMA, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMV Pharmaceuticals	1	0	2	1	2.75
XOMA	0	0	0	0	0.00

PMV Pharmaceuticals presently has a consensus target price of $4.00, suggesting a potential upside of 206.51%. Given PMV Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts clearly believe PMV Pharmaceuticals is more favorable than XOMA.

Earnings & Valuation

This table compares PMV Pharmaceuticals and XOMA”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMV Pharmaceuticals	N/A	N/A	-$77.74 million	($1.42)	-0.92
XOMA	$7.65 million	N/A	N/A	N/A	N/A

XOMA has higher revenue and earnings than PMV Pharmaceuticals.

Insider and Institutional Ownership

90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 10.2% of PMV Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

PMV Pharmaceuticals beats XOMA on 6 of the 9 factors compared between the two stocks.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

About XOMA

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.